[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462840":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":53,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":20,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"blood sampling","EXPERIMENTAL","blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma",[13],"Biological: Blood samples",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Blood samples","Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Valentin HELUAIN, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+33567771439","+33","heluain.v@chu-toulouse.fr",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Toulouse University Hospital","RECRUITING","Toulouse","Occitanie","31300","France","FR",{"type":41,"coordinates":42},"Point",[43,44],1.44367,43.60426,{"lat":44,"lon":43},[47,51],{"name":48,"role":27,"phone":49,"phoneExt":20,"email":50},"Sandra BERNARD, PM","+33561778573","bernard.s@chu-toulouse.fr",{"name":52,"role":24,"phone":20,"phoneExt":20,"email":20},"Valentin HELUAIN",{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100462840","molecular-analysis-of-endoscopic-cytology-samples-supernatant-in-pulmonary-nodules-100462840",false,"NCT05306912","Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules","Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules (Cancer Or Benign Endoscopy) (KOBE)","KOBE","Inclusion Criteria:\n\n* rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule\n* World Health Organization (WHO) Performance status 0-3\n* Informed signed consent\n* Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).\n\nExclusion Criteria:\n\n* Lung cancer diagnosed before the date of the procedure\n* Lung cancer strongly suspected due to mediastinal or extra thoracic lesions\n* Patient under State Medical Assistance\n* Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice","ALL","18 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"NA","Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool.\n\nComplementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound (rEBUS) bronchoscopy is a minimally invasive approach (\\\u003C3% complications) but of limited sensitivity in cases of nodules \\\u003C 20 mm.\n\nThe investigators hypothesized that methylation analysis on cfDNA floating in supernatant derived from rEBUS specimens could improve rEBUS sensitivity",[73,74],"Lung Cancer","Lung; Node",[76,77,78,79,80,81,82],"Circulating free DNA","Methylation","Lung cancer","screening","lung nodule","radial EBUS","endobronchial ultrasound","2026-04-28",{"date":85,"type":86},"2026-04-29","ACTUAL",{"date":88,"type":86},"2022-04-08",{"date":90,"type":67},"2026-12",{"name":5,"class":6},1]